Chinese AI drug discovery startup XtaIPi secures $400m co-led by OrbiMed, HOPU

Chinese AI drug discovery startup XtaIPi secures $400m co-led by OrbiMed, HOPU

Shenzhen-based Chinese AI drug discovery platform XtalPi has raked in $400 million in a Series D round of financing.

The fresh corpus raised by XtalPi brings its market valuation to over 13 billion yuan ($2 billion).

Bring stories like this into your inbox every day.

Sign up for our newsletter - The Daily Brief
Subscribe to Newsletter